Complete financial analysis of KalVista Pharmaceuticals, Inc. (KALV) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of KalVista Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Halla Holdings Corp. (060980.KS) Income Statement Analysis – Financial Results
- Orbite Technologies Inc. (EORBF) Income Statement Analysis – Financial Results
- Times Guaranty Limited (TIMESGTY.NS) Income Statement Analysis – Financial Results
- FNB Bancorp, Inc. (FBIP) Income Statement Analysis – Financial Results
- ECARX Holdings, Inc. (ECX) Income Statement Analysis – Financial Results
KalVista Pharmaceuticals, Inc. (KALV)
About KalVista Pharmaceuticals, Inc.
KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors for diseases with unmet needs. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include KVD001, a plasma kallikrein inhibitor that completed a Phase II clinical trial for the treatment of DME; sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; KVD824, an oral product candidate for the treatment of HAE; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 12.69M | 12.69M | 16.13M | 8.39M | 1.50M | 2.13M | 1.80M | 415.00K | 1.54M |
| Cost of Revenue | 86.17M | 802.00K | 743.00K | 651.00K | 40.19K | 35.02K | 18.24K | 12.67K | 14.66K | 8.29K | 0.00 | 0.00 |
| Gross Profit | -86.17M | -802.00K | -743.00K | 12.04M | 12.65M | 16.09M | 8.38M | 1.49M | 2.12M | 1.80M | 415.00K | 1.54M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 94.87% | 99.68% | 99.78% | 99.78% | 99.16% | 99.31% | 99.54% | 100.00% | 100.00% |
| Research & Development | 86.17M | 80.28M | 70.17M | 41.29M | 40.19M | 35.02M | 18.24M | 12.67M | 14.66M | 8.29M | 4.23M | 1.96M |
| General & Administrative | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 54.28M | 30.60M | 26.45M | 16.64M | 13.03M | 10.93M | 8.86M | 11.18M | 2.65M | 1.61M | 1.40M | 1.41M |
| Other Expenses | -86.17M | 15.64M | 14.72M | 9.93M | 9.83M | 7.68M | 4.39M | 2.33M | 2.03M | 844.00K | -59.00K | 35.00K |
| Operating Expenses | 54.28M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Cost & Expenses | 140.45M | 110.87M | 96.61M | 57.92M | 53.22M | 45.95M | 27.10M | 23.84M | 17.31M | 9.89M | 5.63M | 3.37M |
| Interest Income | 0.00 | 2.23M | 1.09M | 903.00K | 1.83M | 1.40M | 82.00K | 36.00K | 50.00K | 19.00K | 2.00K | 1.00K |
| Interest Expense | 0.00 | 0.00 | 1.09M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 405.00K | 256.00K |
| Depreciation & Amortization | 816.00K | 802.00K | 743.00K | 651.00K | 525.00K | 378.00K | 180.00K | 40.00K | 133.00K | 38.00K | 27.00K | 38.00K |
| EBITDA | -134.28M | -92.11M | -81.60M | -45.59M | -40.02M | -29.44M | -18.53M | -22.30M | -15.15M | -8.05M | -5.25M | -1.76M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | -458.89% | -312.48% | -182.87% | -201.94% | -1,573.80% | -788.05% | -446.29% | -1,264.10% | -114.37% |
| Operating Income | -140.45M | -110.87M | -96.61M | -57.92M | -40.53M | -29.82M | -18.71M | -22.34M | -15.18M | -8.09M | -5.22M | -1.83M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | -456.45% | -319.41% | -184.91% | -222.84% | -1,485.31% | -711.72% | -448.39% | -1,256.87% | -119.18% |
| Total Other Income/Expenses | 5.35M | 17.96M | 14.27M | 11.68M | 11.29M | 9.13M | 2.90M | 3.74M | 3.75M | 863.00K | -462.00K | -220.00K |
| Income Before Tax | -135.10M | -92.91M | -82.34M | -46.24M | -29.24M | -20.69M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | -364.41% | -230.42% | -128.31% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| Income Tax Expense | -8.45M | -18.05M | -13.83M | -1.75M | -124.00K | 124.00K | -1.33M | -5.11M | -5.41M | -863.00K | 462.00K | 220.00K |
| Net Income | -126.64M | -74.85M | -68.51M | -44.49M | -29.12M | -20.82M | -15.81M | -18.60M | -11.44M | -7.23M | -5.68M | -2.05M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | -350.62% | -229.44% | -129.08% | -188.29% | -1,236.90% | -536.15% | -400.55% | -1,368.19% | -133.49% |
| EPS | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| EPS Diluted | -3.44 | -2.68 | -2.80 | -2.33 | -1.64 | -1.38 | -1.53 | -1.92 | -2.40 | -6.17 | -7.83 | -2.83 |
| Weighted Avg Shares Out | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
| Weighted Avg Shares Out (Dil) | 36.79M | 27.89M | 24.47M | 19.09M | 17.75M | 15.08M | 10.32M | 9.71M | 4.77M | 1.17M | 724.80K | 724.80K |
KalVista Pharmaceuticals to Present at 22nd Annual Needham Virtual Healthcare Conference
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced it will participate in a fireside chat at the 22nd...
Wall Street Analysts Think KalVista Pharmaceuticals, Inc. (KALV) Could Surge 145.98%: Read This Before Placing a Bet
The consensus price target hints at a 146% upside potential for KalVista Pharmaceuticals, Inc. (KALV). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness...
KalVista Pharmaceuticals, Inc. (KALV) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?
KalVista Pharmaceuticals, Inc. (KALV) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the...
KalVista Pharmaceuticals Reports Third Fiscal Quarter Results
CAMBRIDGE, Mass. & SALISBURY, United Kingdom--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided an operational update and released financial results for the...
KalVista Pharmaceuticals Presents Data at American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today presented five posters at the American Academy of Allergy, Asthma &...
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)---- $KALV--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual...
KalVista Pharmaceuticals to Present Data at the 2023 American Academy of Allergy, Asthma & Immunology
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today announced the acceptance of multiple abstracts at the 2023 Annual Scientific...
KalVista Pharmaceuticals Provides Progress Updates on Sebetralstat Development
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors, today provided multiple clinical trial and regulatory updates for its lead compound...
KalVista Pharmaceuticals Announces Publication of Sebetralstat Phase 2 Data in The Lancet
CAMBRIDGE, Mass. & SALISBURY, England--(BUSINESS WIRE)--KalVista Pharmaceuticals, Inc. (NASDAQ: KALV), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of oral, small molecule protease inhibitors today announced that results from the phase 2 trial evaluating the efficacy...
What Makes KalVista Pharmaceuticals, Inc. (KALV) a New Buy Stock
KalVista Pharmaceuticals, Inc. (KALV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Source: https://incomestatements.info
Category: Stock Reports